[go: up one dir, main page]

Iveland et al., 2025 - Google Patents

Cytotoxic mechanisms of pemetrexed and HDAC inhibition in non-small cell lung cancer cells involving ribonucleotides in DNA

Iveland et al., 2025

View HTML
Document ID
7923646034275777676
Author
Iveland T
Hagen L
de Sousa M
Liabakk N
Aas P
Sharma A
Kavli B
Slupphaug G
Publication year
Publication venue
Scientific Reports

External Links

Snippet

The cytotoxic mechanisms of thymidylate synthase inhibitors, such as the multitarget antifolate pemetrexed, are not yet fully understood. Emerging evidence indicates that combining pemetrexed with histone deacetylase inhibitors (HDACi) may enhance …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
Reich et al. A multi-omics analysis reveals the unfolded protein response regulon and stress-induced resistance to folate-based antimetabolites
Zeng et al. Inhibition of CDK1 overcomes Oxaliplatin resistance by regulating ACSL4‐mediated Ferroptosis in colorectal cancer
Noronha et al. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer
Liu et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies
Cleary et al. Biomarker-guided development of DNA repair inhibitors
Kategaya et al. Werner syndrome helicase is required for the survival of cancer cells with microsatellite instability
Stover et al. Biomarkers of response and resistance to DNA repair targeted therapies
Tarumoto et al. LKB1, salt-inducible kinases, and MEF2C are linked dependencies in acute myeloid leukemia
Long et al. BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork
Abbotts et al. DNA repair in cancer: emerging targets for personalized therapy
Ou et al. ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield
Locke et al. Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1
Ngoi et al. Targeting ATR in patients with cancer
Troutman et al. Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1
Sousa et al. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells
Liptay et al. Replication fork remodeling and therapy escape in DNA damage response-deficient cancers
Al-Rawi et al. Targeting chromosomal instability in patients with cancer
Yokogawa et al. dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells
Tomasini et al. Analyzing the opportunities to target DNA double-strand breaks repair and replicative stress responses to improve therapeutic index of colorectal cancer
Saha et al. Combinatorial approaches to enhance DNA damage following enzyme-mediated depletion of L-Cys for treatment of pancreatic cancer
Ashok Kumar et al. Genomic landscape of non‐small‐cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency
Chen et al. An RNA damage response network mediates the lethality of 5-FU in colorectal cancer
Wu et al. Mutational landscape of homologous recombination‐related genes in small‐cell lung cancer
Aprile et al. Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype
Ngoi et al. Synthetic lethal strategies for the development of cancer therapeutics